News
Why Investors Are Paying a Premium for EXACT Sciences Corporation
EXACT Sciences Corporation (NASDAQ: EXAS) operates in an industry famous for cutthroat competition that strangles profitability. In this context, the stock's 300% run-up to a nosebleed-inducing....
3 Reasons It's Smart to Buy Celgene's Stock Now
Celgene Corp. (NASDAQ: CELG) shares nose-dived in October following a trial failure and third-quarter financials that failed to impress. However, there are good reasons investors ought to consider....
The Single Biggest Reason Teva Pharmaceutical Industries Imploded and Fell 22% in October
Shares of Teva Pharmaceutical Industries (NYSE: TEVA), a developer of branded and generic drugs and the largest generic drugmaker in the world, tumbled another 22% in October, according to data....
IDEXX Laboratories, Inc. Puts Long-Term Profits Ahead of Short-Term Revenue
On the surface, IDEXX Laboratories's (NASDAQ: IDXX) third quarter wasn't the kind of outstanding report we've come to expect from the animal-testing company, which narrowed its revenue guidance....
What's Behind Gilead Sciences Inc.'s $7.8 Billion Slide in October?
Shares of Gilead Sciences, Inc. (NASDAQ: GILD) slipped 7.5% last month, according to S&P Global Market Intelligence, reducing the biotech's market cap by $7.8 billion. Although the company....
Why Teva Pharmaceutical Is Crashing Today
After the company provided investors with yet another disappointing update to its financial performance, shares in Teva Pharmaceutical (NYSE: TEVA) are losing 15% as of 1 p.m. EDT.It's been tough....
5 Things Pfizer's Management Just Said That You Don't Want to Miss
Forget Pfizer's (NYSE: PFE) third-quarter earnings announcement. The real story lies in what the company's top executives said afterward.The big pharma company reported its third-quarter results....
Align Technologies Keeps Rising; Twitter Finally Has a Good Week
In this segment of the Motley Fool Money podcast, host Chris Hill, Million Dollar Portfolio's Jason Moser and Matt Argersinger, and Motley Fool Pro and Options' Jeff Fischer first reflect on the....
BioMarin Pharmaceutical Inc. on Target for Its 15% Revenue Growth Goal
It was a solid third quarter for BioMarin Pharmaceutical (NASDAQ: BMRN) as the biotech keeps plugging along, increasing sales of its orphan drugs while making progress on its pipeline drug....
How Allergan plc Lost $4 Billion in Q3 and Still Performed Quite Well
Allergan (NYSE: AGN) experienced a miserable third quarter -- even before any financial results from the quarter were known. The pharma stock fell nearly 16% during the quarter, after rising by....
Pfizer Inc. (PFE) Q3 2017 Earnings Conference Call Transcript
Image source: The Motley Fool.Pfizer Inc. (NYSE: PFE)Q3 2017 Earnings Conference CallOct. 31, 2017, 8:00 a.m. EDTOperatorContinue readingSource: Fool.com
Seattle Genetics, Inc.: Double-Digit Revenue Growth, but the Best Is Yet to Come
Sales of Seattle Genetics's (NASDAQ: SGEN) Adcetris in the U.S. and Canada jumped 13% year over year in the third quarter, but it's still a relatively small seller for a cancer drug, especially....
Why bluebird bio Inc. Jumped Higher Today
Shares of biotech bluebird bio (NASDAQ: BLUE) are up 7.3% at 12:24 p.m. EDT, having been up as much as 16.3% today, after the company disclosed data in its abstracts for the American Society of....
3 Worst Performing Stocks in October
Halloween has come and gone, but some stocks have been more tricks than treats. As good as October may have been for a lot of investors, some stocks got totally crushed last month.Trivago (NASDAQ:....
Can Juno Therapeutics Outmaneuver Its CAR-T Competitors?
Novartis(NYSE: NVS) filed for Food and Drug Administration (FDA) approval of its chimeric antigen receptor T-cell therapy (CAR-T), Kymriah, in late-stage diffuse large B-cell lymphoma (DLBCL)....
If I Could Buy Only 1 Stock, This Would Be It
What are the top three things you like in a stock? For me, the answer is pretty easy: I like growth most of all. Everyone wants their stocks to appreciate in value.Second, I like dividends. The....
Ionis Down Big on Analyst Miss
This week, Biogen (NASDAQ: BIIB) reported earnings, and Ionis Pharmaceuticals' (NASDAQ: IONS) stock sold off significantly on the news that its drug Spinraza, which Biogen helps commercialize,....
Why Exact Sciences Shares Are Soaring 11.6% Today
After the company reported better-than-expected top- and bottom-line third-quarter results today, shares of Exact Sciences (NASDAQ: EXAS) are jumping 11.6% at 12:30 p.m. EDT.As many as 20 million....
Novavax Stock Upgraded: 3 Things You Need to Know
Every day, Wall Street analysts upgrade some stocks, downgrade others, and "initiate coverage" on a few more. But do these analysts even know what they're talking about? Today, we're taking one....
Why Geron Corporation Stock Is Jumping Today
Shares of the clinical-stage biotech Geron Corporation (NASDAQ: GERN) rose by as much as 13.5% in early morning trading today, thanks to a Fast Track designation from the U.S. Food and Drug....
Pfizer Inc. Q3 Earnings: The Most Important Things to Know
Pfizer's (NYSE: PFE) overall story so far in 2017 has been a mediocre one. The big pharma company's stock is up year to date, but barely half as much as the S&P 500 index. Although Pfizer....
Exact Sciences' Earnings Hammer Short-Sellers (Again)
Americans have historically done poorly when it comes to sticking to recommended guidelines for colon cancer screening, but a new test launched by Exact Sciences (NASDAQ: EXAS) may be changing....
If Celgene Buys This Biotech, Investors Should Win Big-Time
Celgene (NASDAQ: CELG) has fallen on hard times of late -- or its stock has, at least. At the beginning of October, the biotech's share price was up 25% year to date. By the end of the month,....
Better Buy: Intuitive Surgical, Inc. vs. Johnson & Johnson
With multiple catalysts likely to fuel its growth, the healthcare sector is fertile ground from which investors can reap sizable profits -- if you know where to look.To help you in this regard,....
Celgene Corporation Has "Optionality and Opportunity"
Celgene (NASDAQ: CELG) got crushed after announcing third-quarter earnings, saying revenue would come in at the bottom of previous guidance, and lowering its 2020 guidance. All things considered,....